文章：

基因组调整辐射剂量（GARD）在放射治疗中应用的叙事性综述

Narrative Review of the Use of Genomic-Adjusted Radiation Dose (GARD) in Radiotherapy

原文发布日期：14 August 2025

DOI: 10.3390/cancers17162650

类型: Article

开放获取: 是

英文摘要：

This narrative review examines the genomic-adjusted radiation dose (GARD), a biologically informed framework developed to personalize radiotherapy by integrating tumor-specific genomic data. GARD combines the radiosensitivity index (RSI), based on gene expression, with the linear quadratic model to estimate patient-specific radiation effect. Since its introduction in 2017, GARD has demonstrated prognostic value across multiple cancer types in retrospective studies. This review summarizes key studies evaluating GARD across various tumor types and clinical contexts. Emerging trials, including a Phase II trial in HPV-positive oropharyngeal cancer, aim to validate GARD-guided dosing in precision radiotherapy. Future efforts may focus on refining RSI, addressing tumor heterogeneity, and validating GARD-guided dosing in prospective settings.

摘要翻译： 

本综述探讨了基因组调整放射剂量（GARD），这是一种通过整合肿瘤特异性基因组数据实现个体化放疗的生物信息学框架。GARD将基于基因表达的放射敏感性指数（RSI）与线性二次模型相结合，以评估患者特异性放射效应。自2017年提出以来，回顾性研究已证明GARD在多种癌症类型中具有预后价值。本文综述了在不同肿瘤类型和临床背景下评估GARD的关键研究。新兴临床试验（包括一项针对HPV阳性口咽癌的II期试验）旨在验证GARD指导的精准放疗剂量方案。未来研究可能侧重于优化RSI模型、解决肿瘤异质性，并在前瞻性研究中验证GARD指导的剂量策略。

原文链接：

Narrative Review of the Use of Genomic-Adjusted Radiation Dose (GARD) in Radiotherapy